Leerink lowered the firm’s price target on Kura Oncology (KURA) to $20 from $25 and keeps an Outperform rating on the shares ahead of the company’s Q4 earnings report. Model updates take into account the preliminary Q4 financial results, including Komzifti net product revenue and collaboration revenue, as well as 2026 financial guidance, Leerink adds.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- 3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts
- Kura Oncology reports inducement grants under Nasdaq listing rule
- Kura Oncology’s Promising Clinical Data and Strategic Partnerships Justify Buy Rating
- Positive Outlook for Kura Oncology Driven by Promising Clinical Trials and Strategic Advancements
- Kura Oncology, Kyowa Kirin report combination data for KOMZIFTI with ven/aza